Patents by Inventor Dean Andrew Rivers

Dean Andrew Rivers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds
    Patent number: 8877742
    Abstract: The present invention relates to novel NADPH oxidase II inhibitors and their use in the treatment of diseases mediated by the NADPH oxidase enzymes.
    Type: Grant
    Filed: June 8, 2012
    Date of Patent: November 4, 2014
    Assignee: GlaxoSmithKline Intellectual Property Limited
    Inventors: Deborah W. Chen, Sarah Duncan, Nigel Paul King, Kiew Ching Lee, Sing Yeung Mak, Dean Andrew Rivers
  • NOVEL COMPOUNDS
    Publication number: 20140155375
    Abstract: The present invention relates to novel NADPH oxidase II inhibitors and their use in the treatment of diseases mediated by the NADPH oxidase enzymes.
    Type: Application
    Filed: June 8, 2012
    Publication date: June 5, 2014
    Applicant: GlaxoSmithKline Interllectual Property Limited
    Inventors: Deborah W. Chen, Sarah Duncan, Nigel Paul King, Kiew Ching Lee, Sing Yeung Mak, Dean Andrew Rivers
  • Oxadiazole substituted indazole derivatives for use as sphingosine 1-phosphate (S1P) agonists
    Patent number: 8324254
    Abstract: The present invention provides compounds of formula (I) or salts thereof: having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders mediated by S1P1 receptors.
    Type: Grant
    Filed: April 17, 2008
    Date of Patent: December 4, 2012
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, Gerard Martin Paul Giblin, James Myatt, David Norton, Dean Andrew Rivers
  • Indole derivatives as S1P1 Receptor
    Patent number: 8101775
    Abstract: The invention relates to compounds of formula (I) wherein one of R5 and R6 is hydrogen or R2 and the other is (a) pharmaceutical compositions containing them and their use in the treatment of conditions or disorders which are mediated via the S1P1 receptor.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: January 24, 2012
    Assignee: Glaxo Group Limited
    Inventors: Mahmood Ahmed, James Myatt, David Norton, Dean Andrew Rivers
  • OXADIAZOLE SUBSTITUTED INDAZOLE DERIVATIVES FOR USE AS SPHINGOSINE 1-PHOSPHATE (S1P) AGONISTS
    Publication number: 20100113528
    Abstract: The present invention provides compounds of formula (I) or salts thereof: having pharmacological activity, processes for their preparation, pharmaceutical compositions containing them and their use in the treatment of various disorders mediated by S1P1 receptors.
    Type: Application
    Filed: April 17, 2008
    Publication date: May 6, 2010
    Inventors: Mahmood Ahmed, Gerard Martin Paul Giblin, James Myatt, David Norton, Dean Andrew Rivers
  • OXADIAZOLE DERIVATES AS S1P1 RECEPTOR AGONISTS
    Publication number: 20100048639
    Abstract: The present invention relates to novel oxadiazole compounds of formula (I) having pharmacological activity, pharmaceutical compositions containing them and their use in the treatment of various disorders.
    Type: Application
    Filed: December 19, 2007
    Publication date: February 25, 2010
    Applicant: GLAXO GROUP LIMITED
    Inventors: Mahmood Ahmed, James Myatt, David Norton, Dean Andrew Rivers
  • 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders
    Publication number: 20080318933
    Abstract: The present invention relates to novel indole derivatives such as compounds of the formula (I): which possess antagonist potency at the 5-HT6 receptor and the use of such compounds or pharmaceutically acceptable salts or solvates thereof in the treatment of Alzheimer's disease and other CNS disorders.
    Type: Application
    Filed: October 5, 2005
    Publication date: December 25, 2008
    Inventors: Mahmood Ahmed, Christopher Norbert Johnson, Neil Derek Miller, Peter Henry Milner, Dean Andrew Rivers, David R Witty